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Abstract 
Current techniques to improve bone regeneration following trauma or tumour 
resection involve the use of autograft bone or its substitutes supplemented with 
osteoinductive growth factors and/or osteogenic cells such as mesenchymal stem 
cells (MSCs). Although MSCs are most commonly grown in media containing fetal 
calf serum, human platelet lysate (PL) offers an effective alternative. Bone marrow 
(BM)-derived MSCs grown in PL-containing media display faster proliferation 
whilst maintaining good osteogenic differentiation capacity. Limited pre-clinical 
investigations using PL-expanded MSCs seeded onto osteoconductive scaffolds 
indicate good potential of such constructs to repair bone in vivo. In an alternative 
approach, nude PL-coated scaffolds without seeded MSCs have been proposed as 
novel regenerative medicine devices. Even though methods to coat scaffolds with PL 
vary, in vitro studies suggest that PL allows for MSC adhesion, migration and 
differentiation inside these scaffolds. Increased new bone formation and 
vascularisation in comparison to uncoated scaffolds has also been observed in vivo. 
This review outlines the state-of-the-art research in the field of PL for ex vivo MSC 
expansion and in vivo bone regeneration. To minimise inconsistency between the 
studies, further work is required towards standardisation of PL preparation in terms 
of the starting material, platelet concentration, leukocyte depletion, and the method 
of platelet lysis. PL quality control procedures and its “potency” assessment are 
urgently needed, which could include measurements of key growth and attachment 
factors important for MSC maintenance and differentiation. Furthermore, different 
PL formulations could be tailor-made for specific bone repair indications. Such 
measures would undoubtedly speed up clinical translation of PL-based treatments 
for bone regeneration. 
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Core tip: Human platelet lysate (PL) offers an exciting opportunity for expanding 
mesenchymal stem cells (MSCs), as well as bone regeneration as a scaffold coating. 
In this review we describe the state-of-the-art research in the area of bone 
regeneration utilising PL and MSCs and emphasise the need for standardisation of 
PL preparation and its quality control in order to progress further in this exciting 
area of research. Different PL formulations could be tailor-made for specific scaffolds 
and bone repair indications, both in autologous and allogenic settings. More pre-
clinical and clinical work is needed to progress this research into clinical translation. 
 
Altaie A, Owston H, Jones E. Use of platelet lysate for bone regeneration - are we 
ready for clinical translation? World J Stem Cells 2016; In press 
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INTRODUCTION 
Bone regeneration following trauma, tumour resection or as a result of chronic or 
degenerative bone disease represents a serious clinical problem. The use of autograft 
bone is limited by its volume and accessibility and is known to be associated with 
donor site morbidity and pain[1]. New strategies involve the use of allograft, 
xenograft or synthetic scaffolds, often combined with patient’s own stem cells or 
growth factors. Multipotential stromal cells, also termed mesenchymal stem cells 
(MSCs) reside in the bone marrow (BM) and other connective tissues in humans and 
are quite abundant in vivo making them the preferred choice for use in bone 
regeneration[2]. In the past, MSCs were derived from patient’s own BM and seeded 
on osteoconductive scaffolds following ex vivo culture expansion, these clinical 
studies yielded promising results and good long-term safety profiles[3, 4]. 
However, in most of these studies MSCs were grown in media containing fetal calf 
or fetal bovine serum (FCS/FBS), a source of bioactive molecules required for MSC 
attachment and proliferation. Although FCS is a well known supplement for MSC 
expansion, its major drawback is a possibility for triggering immunological 
responses in the recipient against xenogenic antigens present in FCS. In this review 
we will describe the current knowledge on the use of a potential alternative to FCS, 
human platelet lysate (PL), for ex vivo MSC expansion and in vivo bone regeneration, 
highlighting various steps in PL manufacture and their possible impact of PL 
bioactivity.  
 
THE USE AND BENEFITS OF HUMAN PLATELET-RICH PLASMA AND PL AS 
FCS REPLACEMENTS 
As mentioned above, there is an urgent need for an alternative to FCS as a medium 
supplement. The straightforward substitute is human serum (HS) and successful 
expansion of MSCs with the use of autologous serum has been achieved in several 
independent studies[5, 6]. On the other hand, the reports on the efficacy of allogenic 
HS have been contradictory[7, 8]. One important consideration is the age of the donor, 
as serum from elderly individuals seems inadequate to support MSC proliferation or 
differentiation[9, 10]. 
An alternative to HS is platelet-rich plasma (PRP), which was shown to enhance 
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MSC proliferation in ex-vivo culture as early as 2006[11]. PRP is commonly produced 
from whole blood collected using EDTA as an anticoagulant. A low-speed 
centrifugation (10 min at 230–270 g) is performed first, followed by high-speed 
centrifugation (10 min at 2300 g or higher). The supernatant is called platelet-poor-
plasma (PPP). Subsequently, 9/10th of the supernatant (PPP) volume is removed, 
and the platelet pellet is resuspended in 1/10th PPP volume, which is then referred 
to as PRP[12]. To activate platelets and hence maximise the release of growth factors 
from platelets’ alpha granules into the PRP, thrombin is added, the product is called 
tPRP[13].  
PRP as a supplement for MSC culture has several drawbacks. Firstly, not all growth 
and attachment factors are released from platelets without their activation[14, 15]. 
Secondly, the presence of fibrinogen and the formation of fibrin clots after thrombin 
stimulation are suggested to be the reasons for the partial loss of platelet derived 
growth factor BB (PDGF-BB) content. A substantial amount of released PDGF-BB 
was found to be trapped in fibrin glue, so the maximum amount of PDGF-BB could 
not be obtained[13]. Thirdly, the storage temperature of the PRP should be no less 
than 4°C. If the PRP is frozen at -20°C or -80°C, it could no longer be referred to as 
PRP as freezing releases growth factors and cytokines from the platelets. Yet some 
early studies have referred to platelet concentrates which have been frozen as 
PRP[11].  
In many ways, these drawbacks can be mitigated with the use of PL instead of PRP. 
Shish and Burnouf summarises the main production methodes of PL materials for 
stem cells expansion and regenerative medicine[12]. During PL manufacture platelets 
are lysed, and sometimes activated prior to their lysis, in order to release the 
maximum amount of bioactive molecules and reduce batch-to-batch variation. 
Filtering is performed to remove cellular debris and WBC contamination is 
minimised by leukodepletion steps. In order to use pooled PL, the blood group type 
being used for PL preparation is important to avoid immunogenic reaction [16]. 
Although MSCs have been shown not to absorb immunogenic ABO antigens from 
culture media containing FCS or human substitutes such as AB serum and PRP, 
MSC could absorb these antigens from the fresh AB plasma used for washing and 
cell infusion[17]. In order to prevent contact of MSCs to ABO blood group antigens, 
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platelet concentrates derived from blood group O are combined with plasma from 
blood group AB[12, 15, 18].  
Recent studies have shown that MSC population doublings and expansion kinetics 
were significantly enhanced in PL-supplemented BM MSC cultures compared with 
cultures supplemented with FCS, HS, or tPRP[18, 19]. Clinically relevant numbers of 
MSCs could be obtained within the first to second passage in PL-supplemented 
cultures. This rapid increase in MSC yields could be due to increased MSC 
attachment (evident as increased colony numbers) as well as their faster proliferation 
(evident as bigger colony sizes), illustrated in Figure 1.  
Several other studies have shown that media supplemented with PL shortened MSC 
expansion time, while preserving MSC phenotype and differentiation capacities[20-24]. 
BM MSC grown with 100 mL/L PL efficiently differentiated into the adipogenic, 
osteogenic and chondrogenic lineages[25-28]. Furthermore, PL was shown to be 
superior to FCS for BM MSC adipogenesis differentiation[26, 27]. There is also 
evidence that PL soluble factors can regulate osteogenesis via RUNX2- and Osx-
independent pathways[25, 29]. The effect of PL on MSC immunoregulation capacity 
remains to be further explored. One study suggested that the fibrinogen depletion 
step was necessary in PL manufacture in order to prepare clinical-grade MSCs 
intended for immunomodulation[30]. In another study, inhibition of T cell 
proliferation was observed equally in MSCs cultured in PL and FCS[18]. 
The other advantage of PL is that it can be prepared from expired platelet 
concentrates (older than 5 days) that are no longer suitable for use in blood 
transfusion. The PL produced from expired platelets has been shown to have the 
same impact on MSC growth and osteogenic differentiation as PL from fresh 
platelets in one study[28]. Freezing and thawing seems to be the most effective 
process to release growth factors in platelet samples, because both WBCs and 
platelets are destroyed by this procedure and growth factors are not stable in 
plasma[31]. 
 
GROWTH AND ATTACHMENT FACTORS PRESENT IN PL 
Contained within the alpha granules of platelets are a broad spectrum of growth 
factors that have been shown to enhance MSC proliferation. These include PDGF-
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AA, PDGF-AB/BB, transforming growth factor-β1 (TGF-β1) (Table 1), epidermal 
growth factor (EGF), basic fibroblast growth factor (bFGF), insulin-like growth factor 
1 (IGF-1), and vascular endothelial growth factor (VEGF) with low batch-to-batch 
variability, and most of these growth factors are stable for up to 14 days[32, 33]. The 
higher level of these growth factors and cytokines in PL compared to FCS and HS 
could in part explain why PL-expanded MSCs grow faster, however, only a few 
studies have presented comparisons of the growth factor levels in PL compared to 
FCS [15, 26, 34]. Interestingly, PDGF-BB was not detected in FCS[26, 34]. When PDGF-BB 
was low in the growth medium, BM MSC cell yield was found to be poorer in 
comparison to a higher PDGF-BB level media[27]. Also, the inhibition of PDGF-BB in 
medium supplemented with 100 mL/L PL significantly decreased MSC 
proliferation[19, 33]. However, the addition of the equivalent concentration of 
recombinant PDGF-BB to the media did not significantly enhance MSC proliferation 
[33]. Therefore, it is possible that PDGF-BB could be the main but not the only factor 
responsible for enhanced MSC proliferation and other growth factors, for example 
TGF-β1 and bFGF are involved. 
The presence of the chemokines and attachment factors in the MSC growing media 
is equally important. In relation to chemokines and soluble adhesion molecules, PL 
has been shown to contain chemokine (C-C) ligand 5 (CCL5/RANTES), CXCL1, 
CXCL2 and CXCL3 and, in particular, very high concentrations of soluble cluster of 
differentiation 40 ligand (sCD40L), soluble vascular cell adhesion molecule 
(sVCAM), and soluble intracellular adhesion molecule (sICAM)[33]. The attachment 
factors are important for adhesion of MSCs to plastic surfaces whereas chemokines 
ensure MSC migration and equal distribution across these surfaces.  
 
IN VIVO BONE FORMATION USING PL EXPANDED MSCS IN PRE-CLINICAL 
INVESTIGATIONS 
As mentioned above, PL provides several advantages over FCS for MSC expansion, 
however, PL preparation methods remain varied. Table 1 summarises the most 
commonly used methods to obtain PL including those used for pre-clinical 
investigations[25, 35-38]. Most of the studies shown in Table 1 prepared PL via 
apheresis in a closed system using centrifugation to separate cells by weight (specific 
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gravity), or filtration to separate cells by size, or used a combination of both, with the 
resulting platelet count of 1x109 platelet/mL. Such platelet concentrates have a larger 
volume (typically 200–300 mL), and their total platelet content is about 6–8 fold 
higher of a platelet concentrate from a single whole-blood donor[12]. Although it is 
known that the apheresis procedure results in low WBC count, precise levels of 
WBCs present in the platelet concentrate were not reported in these studies. 
Alternatively, two studies used the buffy coat procedure[15, 18] to obtain a platelet 
concentrate and then combined it with inline filtration to reduce WBC 
contamination.  
Only a few pre-clinical studies investigated in vivo bone generation using PL-
expanded BM MSCs (Table 2). All of these studies have reported some success in 
new bone formation in vivo. Notably there were differences in scaffolds and animal 
models, making direct comparisons of bone repair outcomes difficult (Table 2). Only 
two of the five selected studies succeeded to present the results of in vivo bone 
formation on a scaffold seeded with MSCs grown fully with PL without any 
exposure to FCS[25, 35]. Other studies introduced FCS at different stages of the study - 
either for MSC expansion purposes[36, 37] or for in vitro seeding of MSCs onto the 
scaffold[37]. To fully eliminate FCS-exposure for clinical translation, it is important to 
use PL from the beginning and throughout all stages of investigation. Pre-coating 
scaffolds with PL is likely to be advantageous for MSC attachment. With the use of a 
natural xenograft bone scaffold, it is possible to achieve good attachment and 
proliferation of solely PL-expanded BM MSCs by 3 hours incubation of the BM MSC 
in DMEM supplemented with 50 mL/L PL media, as illustrated on Figure 2.  
 
IN VITRO AND IN VIVO BONE FORMATION USING PL COATED 
SCAFFOLDS  
Seeding exogenous MSCs onto a scaffold prior to implantation may not be necessary 
for repairing some types of bone defects. In this scenario, the combination of PL with 
a ‘nude’ bone scaffold could be an attractive answer to target homing, attachment 
and differentiation of neighbouring endogenous MSCs to the repair site. The initial 
in vitro studies investigating this varied in scaffold type and the method of 
combining PL with the scaffold. The simplest method involved overnight incubation 
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of a hydroxyapatite/beta-tricalcium phosphate (HA/β-TCP) scaffold immersed in 
PL[37]. Methods utilising polymer based scaffolds involved layer by layer assembly 
[39] or combining PL loaded nanoparticles with a polymer powder[40]. Of note, ‘soft’ 
PL loaded scaffolds have also been explored for use in wound healing[41] and 
cartilage regeneration[42], where methods included overnight incubation of polymer-
fibrin scaffolds with a fibrinogen and PL solution or mixing PL with a polymer 
solution to create a hydrogel, respectively. Freeze-thaw cycles, using at least two 
rounds were the most common method of preparing PL from PRP. 
A concern remains whether PL proteins could block the scaffolds’ pores, thus 
preventing cell infiltration into scaffold. However, a similar scaffold pore size and 
3D structure was reported after the addition of PL in two studies[40, 42]. Growth factor 
release from PL loaded scaffolds varied between studies, where 50ml/L growth 
factor release after 1 day[40] or 2 days[41] was reported, with 91ml/L release by 7 
days[41]. Importantly, the bioactivity of growth factors from loaded scaffolds was 
comparable to PL controls up to 7 days[41]. When MSCs were seeded onto the 
scaffolds (all expanded in 100 mL/L FCS), in vitro cell adhesion and migration 
appeared to be improved by the addition of PL[37, 40, 42]. Furthermore, the presence of 
PL appeared to induce faster osteogenic differentiation[40]. When a non-
osteoconductive polymer scaffold was used, Ca2+ was deposited throughout the 
scaffold indicating that MSCs differentiated into osteoblasts[39]. 
Some studies progressed to investigate the PL coated scaffolds and membranes in 
vivo. In one study a ‘healing impaired’ diabetic mouse model for full thickness skin 
wounds was used. At 15 days post injury the PL loaded scaffold group had 
significantly smaller open wound measurements in comparison to controls [41]. 
Further histological evaluation showed higher levels of collagen deposition[41]. In 
another aforementioned study (Table 2), HA/β-TCP scaffolds, PL loaded or 
unloaded seeded with MSCs were inserted subcutaneously into SCID mice for 7 
weeks[37]. Evidence of new bone formation and vascularisation was seen in PL 
coated compared to uncoated scaffold controls[37]. PL coated scaffolds without prior 
MSC seeding were used as controls; however, this data was not described in the 
paper. In the future this type of data could provide an exciting insight into whether 
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pre-seeding with MSCs is needed or if the PL coating is enough to encourage in vivo 
bone formation. 
Based on the available literature it can be concluded that there are two types of PL 
incorporation into a scaffold, either simply by overnight incubation of a pre-
fabricated scaffold with PL or through addition of PL into the scaffold 
manufacturing process. The former of which has in vivo evidence that it may 
improve bone regeneration. However, the optimal technique of PL incorporation 
onto a scaffold is likely to depend on the nature of the scaffold itself (chemistry, 
porosity, its basic architecture) as well as its intended clinical use. For example, PL-
loaded scaffold intended for use as ‘hard’ bone void filler, should aim to achieve 
faster MSC differentiation. On the other hand, PL loaded onto a ‘soft’ guided bone 
regeneration device (a polymer or natural membrane) should speed up MSC homing 
and proliferation rather than to induce their differentiation. These disparate 
objectives could be achieved by fine-tuning PL formulations and using different 
methods of PL incorporation into the desired scaffold. 
For orthopaedic applications, ideally ‘off-the-shelf’ PL-loaded and packaged 
scaffolds could be made available to surgeons in the operating theatre, however 
currently no data exists on long-term storage, sterility and stability of PL-loaded 
scaffolds. Alternatively, commercially available scaffolds could be loaded with 
autologous PL during surgery. Although theoretically possible, it remains unclear 
whether PL preparation and loading can be achieved to fit into intra-operative time 
frames, so far, only overnight incubation has been evaluated pre-clinically. Further 
investigation into speeding up the production of autologous PL for use in surgery, as 
well as whether allogenic ‘bottled’ PL can be produced consistency in larger volumes 
to a controlled standard is needed for this area to progress. 
 
FUTURE CONSIDERATIONS FOR THE USE OF PL IN BONE REPAIR 
One of the advantages of PL is its relative ease of preparation (Figure 3A). 
Nevertheless, there are a few points that should be considered if PL is used for 
clinical translation for bone repair (Figure 3B). The blood collection method, WBC 
reduction step, platelet concentration method, freeze and thaw temperatures, and 
addition of the anticoagulation factors to each of these steps might affect the growth 
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and attachment factors levels in PL that in turn influence MSC growth and 
differentiation. 
The first step of the PL preparation is the collection of the platelet concentrate either 
by apheresis, buffy coat or PRP methods. Buffy coat and PRP methods are 
procedures to obtain platelet concentrate from whole blood by two step 
centrifugation, for buffy coat first with low speed spin and second with high speed 
spin. Conversely, the PRP method starts with high speed spin followed by a low 
speed spin (Figure 3A). However, study variations are expected as apheresis leads to 
a high platelet count and lower WBC contamination compared to the buffy coat and 
PRP methods[31, 43, 44]. The buffy coat method tends to reduce the WBC 
contamination, compared to PRP[44]. The leucocyte reduction step is vital as WBC-
derived molecules could influence MSC expansion[45]. Upon WBC lysis, matrix 
metalloproteinases (MMPs) and free oxygen radicals may be released that could lead 
to MSC detachment and apoptosis[46]. Some studies tend to apply extra 
centrifugation steps to reduce WBCs in the platelet concentrates but a degree of 
WBC contamination can still be seen, which also impacts the growth factors’ levels in 
PL[31, 47]. Therefore, it is imperative to include rigorous leucocyte depletion steps in 
PL preparation procedure, as centrifugation steps remain insufficient. To release 
growth factors from the platelet concentrates, mechanical bursts of freeze and thaw 
cycles are implemented [18, 25, 26, 31, 34, 37]. Most studies used -80°C as the freeze point 
and 37°C as the thaw point. However, the freeze and thaw temperatures seem to 
affect the yields of the growth factors in PL. In order to obtain the highest growth 
factors levels, one study recommended the -196°C/4°C cycle, as PDGF-BB levels in 
PL from PRP using this cycle were significantly higher than from PRP using -
80°C/4°C cycle[27].∀
Since PL contains fibrinogen and coagulation factors, adding anticoagulants is vital. 
Heparin is usually added to PL-media before use. However, the concentration of 
heparin should not exceed 0.61 IU/mL when using unfractionated heparin or 0.024 
mg/mL for low-molecular-weight heparin[48]. This is because higher concentrations 
of heparin may negatively affect MSC proliferation, colony formation and 
differentiation[48]. Additionally, available commercial heparin, which is 
manufactured primarily from porcine sources, has been shown to cause adverse 
reactions to human tissues, despite being approved for human use[30, 49, 50]. These 
concerns are avoided with the use of the human origin heparin or by preparing PL 
from serum instead of plasma[27]. 
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ARE WE READY FOR CLINICAL TRANSLATION?  
PL represents a new and exciting opportunity for bone defect repair, either as a cell 
culture supplement for MSC expansion or as a coating agent for osteoconductive 
scaffolds and guided bone regeneration devices. PLs contain a multitude of bioactive 
factors that act synergistically to facilitate MSC attachment, proliferation and 
differentiation. Still, the exact amounts and ratios between these bioactive molecules 
remain to be established in order to achieve the desired and timely therapeutic effect 
on bone repair. For this, a consorted scientific and industrial effort is needed to 
establish standard protocols and quality control procedures for PL production that 
are tailor-made for intended therapeutic use. This can be split into two long term 
areas of investigation, primarily, large scale production of allogenic PL and 
secondly, fast small scale production of autologous PL exclusively for use in acute 
surgery. 
Additionally, the time scale of growth factor release from scaffolds needs to be 
detailed to further understand the potential effect on bone regeneration. In order to 
have standard PL, a minimal quality control criteria is needed. For example, a 
minimum of 3-4 fold increase in the platelet concentration compared to the start 
point, the levels of PDGF-BB and the degree of WBC contamination, could be three 
factors that can serve as initial quality control criteria of standard PL. Finally, while 
the existing pre-clinical evidence on the use of PL-expanded MSCs or PL-coated 
scaffolds is encouraging, clinical studies investigating the benefits of PL-based 
products for improving bone regeneration are still lacking. Such evidence is 
definitely required to progress further in this field.  
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Table 1 Common methods of PL preparation 
Studies 
Platelet 
collection 
Leucocyte 
reduction 
Freeze & thaw 
temperature 
Anti-coagulation 
factors 
PDGF Level 
[15] Buffy coat Inline 
filtration 
-30°C/37°C 100 IU/mL H  (AA) 7424 ± 1043 
pg/mL* 
(BB) 4655 ± 1353 
pg/mL 
(AB) 40458 ± 1791 
pg/mL  
[18] Buffy coat Inline 
filtration 
–30°C/37°C 2 IU/mL H  Higher than FCS 
[38] Apheresis NR -20 °C/37°C NR NR 
[25] Apheresis NR -80°C/NR 2 IU/mL H  NR 
[36] NR NR -80°C/NR 10 IU/mL H NR 
[51] Apheresis NR -80°C/37°C 2 IU/mL H  (AB) 530 ± 60 pg/! L  
[37] Apheresis NR -80°C/NR NR (AA) 19596 pg/mL 
(BB) 22329 pg/mL 
H – heparin; bold+highlight – pre clinical investigation; * - measured in media contain 10ml/L PL; 
NR – not reported; PDGF – platelet derived growth factor; AA, AB and BB refer to different isotypes 
of PDGF 
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Table 2: Summary of pre-clinical studies with PL-expanded BM MSCs aimed at bone regeneration 
Studies 
Animal 
model 
MSC source 
MSC 
expansion 
media 
(Supplements)  
Construct 
type 
Scaffold 
pre-coating 
before 
loading 
with MSCs 
Construct in 
vitro culture 
before 
implantation 
(supplements)  
[38] Mouse Iliac crest 
BM 
50 mL/L PL BCP + 2x10
5 
MSCs  
A 10
-8 M DEX 
[36] Sheep Iliac crest 
BM 
200 mL/L FCS  Rat-tail-
derived 
collagen + 
4x10
7 MSCs 
PL  NR 
[37] Mouse Iliac crest 
BM 
100 mL/L FCS HA(65%)+ 
β-TCP(35%)+ 
3x10
5 MSCs  
PL for 24 
hours 
100 mL/L FCS  
[25] Mouse 
 
Iliac crest 
BM 
50 mL/L PL HA(65%)+ 
β-TCP 
(35%)+ 
MSCs* 
 PL for 24 
hours 
50 mL/L PL  
[35] Mouse Iliac crest 
BM 
50 mL/L PL BCP+ 4x10
6 
MSCs 
A 80 mL/L PL 
BCP – biphasic calcium phosphate, HA+β-TCP – hydroxyapatite/beta-tricalcium phosphate 
A – absent, DEX- dexamethasone, NR – not reported, * MSC number not reported. Bold+ highlight – no 
FCS was used at any stage of investigation. 
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Figure 1: The enhancement of MSC colony formation in PL-cultured BM aspirates 
from a single patient. Day-14 colonies formed from 200 ! L of fresh BM aspirate 
seeded on plastic culture dish with either 100 mL/L FCS (A) or 100 mL/L PL (B). 
Higher magnification (40X) of individual colonies grown in 100 mL/L FCS (C) or 100 
mL/L PL (D). Quantified analysis of the average size of the colonies in pixels (E). 
!)∀
The average number of colonies (F). Colony number and size were analysed using 
NIS Elements BR Nikon software.  
 
 
Figure 2: The attachment of PL-expanded BM MSCs on Orthoss scaffold. BM 
MSCs at passage 2 were incubated with the scaffold by continuous mixing at 37°C 
and 5% CO2 for 3 hours with DMEM+50 mL/L PL. The scaffold was then washed 
and incubated for 10 days with DMEM+50 mL/L PL. SEM image illustrate MSCs on 
the scaffold  (A). Higher magnification demonstrates MSC morphology on the 
scaffold surface (B). MSC cells, Orthoss scaffold.  
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Figure 3. Summary of the current methods used for PL preparation. Step by step 
guide of the PL preparation methods (A). Suggested stages to standardise in PL 
preparation (B). 
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